Literature DB >> 11003051

In vitro and in vivo stability of new multilamellar vesicles.

O Freund1, J Amédee, D Roux, R Laversanne.   

Abstract

Factors affecting multilamellar vesicles transport to the blood compartment after oral administration to rats were evaluated first in vitro. A high entrapment of protein A was obtained when the vesicles were prepared by shearing a lyotropic lamellar phase composed of soybean phosphatidylcholine, cholesterol and polyoxyethylene alcohol (C12H25(OCH2CH2)4OH) as neutral detergent. In vitro tests showed that these vesicles (spherulites) were stabled in 50% of fetal calf serum, in acidic (pH 3) or basic (pH 10) buffers, in pancreatin but are partially lysed in 20mM bile salts. Oral administration of spherulites entrapping 111In-NTA in fasting rats showed a increase of radioacticivity in blood. This could be explained by passage of some spherulites in the enterocytes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11003051     DOI: 10.1016/s0024-3205(00)00640-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug.

Authors:  Zerrin Sezgin-Bayindir; Mustafa Naim Antep; Nilufer Yuksel
Journal:  AAPS PharmSciTech       Date:  2014-09-10       Impact factor: 3.246

2.  Multi-scale characterization of lyotropic liquid crystals using 2H and diffusion MRI with spatial resolution in three dimensions.

Authors:  Diana Bernin; Vanessa Koch; Magnus Nydén; Daniel Topgaard
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

3.  Trans-ε-Viniferin Encapsulation in Multi-Lamellar Liposomes: Consequences on Pharmacokinetic Parameters, Biodistribution and Glucuronide Formation in Rats.

Authors:  Pauline Beaumont; Chrystel Faure; Arnaud Courtois; Michael Jourdes; Axel Marchal; Pierre-Louis Teissedre; Tristan Richard; Claude Atgié; Stéphanie Krisa
Journal:  Nutrients       Date:  2021-11-24       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.